Perrigo, one of the world’s largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster.
van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink.
He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels.
The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance Business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.
In his new position as General Manager, Geiger will be responsible for leading Perrigo’s commercial organisations in Germany, Austria, and Switzerland.
Commenting on his appointment, Ronald van Workum said: “I am very pleased to have been promoted to this position within Perrigo. I will continue to drive the growth of the business as well as Perrigo’s commitment to providing accessible, high quality and affordable self-care products. Key to this is working closely with all our retail partners. I will bring my international leadership skills to the German market and develop the business in the DACH region. We are creating a strong, positive team dynamic that combines everyone’s vast experience.”
Tobias Geiger explained as follows: “As of January 2023, Perrigo’s DACH cluster has fully integrated the brands of HRA Pharma, (including Compeed) into its business activities. As always, our goal is to put our customers and consumers at the heart of everything we do. These new brands represent an exciting opportunity to expand our offering and bring high quality, affordable self-care products to even more consumers. For our employees, this means a positive start to 2023 at our new office location for the DACH organisation in the centre of Stuttgart.”